Annals of Surgical Oncology

, Volume 21, Issue 4, pp 1352–1360 | Cite as

Analysis of Bevacizumab-based Preoperative Radiochemotherapy in Patients with Locally Advanced Rectal Cancer on Surgery-associated Spectrum of Complications

  • Kathrin Dellas
  • Johannes Buller
  • Gregor Jürgen Görtz
  • Michael Richter
  • Thomas Höhler
  • Dirk Arnold
  • Tobias Keck
  • Jürgen Dunst
  • Helmut Zühlke
Colorectal Cancer



Preoperative radiochemotherapy (RCT) is a standard of care for patients with locally advanced rectal cancer (LARC; stages II and III). Results of our phase II study (BevXelOx-RT) have shown that this regimen is feasible but without a significant improvement of pathological complete response. Whether preoperatively administered bevacizumab, due to its specific toxicity profile, leads to increased rates of surgical complications is currently a subject for debate. This analysis focusses on the surgery-associated spectrum of complications.


Data from 62 patients with rectal cancer (uT3-4; N0/1, M0) of the phase II trial were analyzed. Patients received radiotherapy (50.4/1.8 Gy fractions), simultaneous bevacizumab 5 mg/kg (d1, d15, d29), and capecitabine 825 mg/m2 twice daily (d1–14, d22–35), oxaliplatin 50 mg/m2 (d1, d8, d22, d29). Four to six weeks after RCT, surgical resection was performed.


Overall, 69/69 patients underwent surgery, and 66 (95.7 %) patients had R0 resection. Surgery was mainly conducted (in 66 %) by highly experienced surgeons (>20 resections of rectal cancer/year) with differences between the institutions due to the operative procedures but without effects on the rate of R0 resection or complications. The average duration of surgery was 239 min (±10). Frequency of multivisceral resections (11 %), intraoperative (8 %) and postoperative (43 %) complications were all in the expected range. In particular, we did not observe an increased rate of postoperative bleedings (3 %). The postoperative mortality rate was 0 %.


Quantity and the kind of surgery-associated spectrum of complications followed by a preoperative bevacizumab-containing RCT regimen in patients with LARC were in line with comparable trials of bevacizumab-based approaches.


  1. 1.
    Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-88.PubMedCrossRefGoogle Scholar
  2. 2.
    Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-1123.PubMedCrossRefGoogle Scholar
  3. 3.
    Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-5.PubMedCrossRefGoogle Scholar
  4. 4.
    Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740.PubMedCrossRefGoogle Scholar
  5. 5.
    Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer. 2012;48(1):37-45.PubMedCrossRefGoogle Scholar
  7. 7.
    Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):124-9.PubMedCrossRefGoogle Scholar
  8. 8.
    Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76(3):824-30.PubMedCrossRefGoogle Scholar
  9. 9.
    Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15(8):845-51.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020-6.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys. 2007;68(2):472-8.PubMedCrossRefGoogle Scholar
  12. 12.
    Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol. 2013;8(1):90.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Arnold D, Seufferlein T. Targeted treatments in colorectal cancer: state of the art and future perspectives: Gut. 2010;59(6):838-58.PubMedCrossRefGoogle Scholar
  14. 14.
    Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173-80.PubMedCrossRefGoogle Scholar
  15. 15.
    Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26(32):5254-60.PubMedCrossRefGoogle Scholar
  16. 16.
    Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21(4):309-15.PubMedCrossRefGoogle Scholar
  17. 17.
    Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19-23.PubMedCrossRefGoogle Scholar
  18. 18.
    Landry JC, Feng Y, Cohen SJ, Staley CA 3rd, Whittington R, Sigurdson ER, et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119(8):1521-27.PubMedCrossRefGoogle Scholar
  19. 19.
    Liang JT, Lai HS, Cheng KW. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. Surg Endosc. 2011;25(1):305-8.PubMedCrossRefGoogle Scholar
  20. 20.
    Marusch F, Gastinger I, Schneider C, Scheidbach H, Konradt J, Bruch HP, et al. Laparoscopic Colorectal Surgery Study Group (LCSSG). Experience as a factor influencing the indications for laparoscopic colorectal surgery and the results. Surg Endosc. 2001;15(2):116-120.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim JS, Hur H, Kim NK, Kim YW, Cho SY, Kim JY, et al. Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure. Ann Surg Oncol. 2009;(16):1266-1273.PubMedCrossRefGoogle Scholar
  22. 22.
    Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003;21(16):3098-3104.PubMedCrossRefGoogle Scholar
  23. 23.
    Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25(1):110-117.PubMedCrossRefGoogle Scholar
  24. 24.
    Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg. 2005;200(6):876-882.PubMedCrossRefGoogle Scholar
  25. 25.
    Hospers GA, Punt CJA, Tesselaar ME, Cats A, Havenga K, Leer JW, et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer: a phase I–II multicenter sdtudy of the Dutch Colorectal Cancer Group. Ann Surg Oncol. 2007;14(10):2773–2779.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Swellengrebel HA, Marijnen CA, Verwaal VJ, Vincent A, Heuff G, Gerhards MF, et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Surg. 2011;98(3):418-426.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Kathrin Dellas
    • 1
  • Johannes Buller
    • 3
  • Gregor Jürgen Görtz
    • 3
  • Michael Richter
    • 4
  • Thomas Höhler
    • 5
  • Dirk Arnold
    • 6
  • Tobias Keck
    • 7
  • Jürgen Dunst
    • 1
    • 2
  • Helmut Zühlke
    • 3
  1. 1.Department of Radiooncology Kiel/LuebeckUniversity of KielKielGermany
  2. 2.Department of Radiooncology Kiel/LuebeckUniversity of LuebeckLuebeckGermany
  3. 3.Department of SurgeryPaul-Gerhard-StiftungWittenbergGermany
  4. 4.Coordination Center for Clinical TrialsHalle (Saale)Germany
  5. 5.Prosper Hospital RecklinghausenRecklinghausenGermany
  6. 6.Department of Medical OncologyTumor Biology Center FreiburgFreiburgGermany
  7. 7.Department of SurgeryUniversity of LuebeckLuebeckGermany

Personalised recommendations